Compare TG Therapeutics Inc (TGTX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vital Farms Inc — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Vital Farms Inc trades at $9.33 (market cap $405.27M). The key difference: TG Therapeutics Inc is far larger — about 20.1× Vital Farms Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vital Farms Inc for 14 Days on average.
| TGTX | VITL | |
|---|---|---|
Market Cap | $8.16B | $405.27M |
Volume | 1,735,121 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $59.06 | $43.40 |
52-Week Low | $26.94 | $8.28 |
Typical Hold Time | 16 Days | 14 Days |
Enterprise Value | $8.37B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Vital Farms (VITL) trades at $9.435, up 2.11% today, amid a challenging period marked by volatile earnings and a bearish technical signal. The stock shows weak profitability with a net income margin of 0.02% in 2026, though valuation ratios like P/S of 0.55 appear attractive. Recent news highlights strategic review for a potential sale, with price targets ranging from $10 to $20. Cash flow remains negative, driven by heavy investing activities, while institutional interest persists with new acquisitions.
The outlook is mixed: analyst consensus is bullish with a $13.11 target, but near-term risks include pricing pressure in the egg market and earnings volatility. Recovery hinges on stabilizing supply costs and executing strategic options. Investors should weigh low valuation against operational challenges and industry headwinds for potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
